One number sits at the center of this new cancer research: the glucocorticoid receptor. It is a single protein. It is the target.
Behind that protein lies another number: decades. That is how long scientists have watched cancer deploy a simple, maddening trick.
Tumor cells go dormant. They stop dividing. They become invisible to chemotherapy.
They wait. When the coast is clear, they wake up.
The disease returns. Now a team at ETH Zürich has built a molecule that goes after that receptor, but only where and when it is told to. The molecule is called a photoPROTAC.
It is inert in the dark. Shine a specific color of light on it, and it destroys the receptor. Keep the light off, and it does nothing.
This is not a cure. It is a tool.
But it is a tool for a problem that has no good tools right now.
The numbers that matter
First, the receptor. The glucocorticoid receptor is a sensor inside cells. It reacts to stress hormones.
In some solid tumors — lung cancer is one example — when that receptor switches on, it pushes the cancer cells into a drug-resistant, dormant state. The cells stop growing.
They stop dying. They just sit there. Second, the obstacle.
The obvious fix would be to destroy that receptor everywhere in the body. But the same receptor does important work outside tumors.
It calms inflammation. Removing it systemically would cause real damage. That is the catch, and it has blocked researchers for years.
Third, the solution. The photoPROTAC is a class of molecules engineered to destroy only the receptor inside the tumor. The light is the switch.
No light, no action. The work was led by Erick M.
Carreira and Katharina Gapp. Their findings were published in the Proceedings of the National Academy of Sciences. It is a precision approach.
But precision is hard in biology. The body is not a clean circuit board.
Light does not penetrate deep tissue easily. Delivering the molecule and the light to the same spot, inside a solid tumor, inside a living patient — that is not solved yet. The paper describes a proof of concept.
It works in a dish. The next steps are not specified in the report. Still, the core idea is starkly simple.
Cancer hides by putting itself to sleep. The glucocorticoid receptor is the key to that hiding strategy, at least in certain cancers.
Hit the receptor, and you might wake the cells up, or kill them, or both. The photoPROTAC gives researchers a way to hit that receptor inside a tumor and leave the rest of the body alone. The stakes are high.
This is not about a single drug. It is about a strategy.
For decades, researchers have struggled to shut down this hiding strategy without causing serious harm elsewhere. That struggle is the backdrop. The photoPROTAC is one attempt to end it.
What is at stake, the researchers said, is the ability to probe, and possibly disrupt, that cellular sleep state. That is the goal. The molecule is the means.
The light is the trigger. It is early.
It is narrow. But it is a new direction. And in a field where the same dead ends have been hit for decades, a new direction is something.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “ETH Zürich Develops Light-Activated Molecule Targeting Dormant Cancer Cells”, “description”: “One number sits at the center of this new cancer research: the glucocorticoid receptor. It is a single protein. It is the target. Behind that…”, “datePublished”: “2026-07-05T17:12:00+00:00T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Beatrice Ferrari”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
